Equal Safety of JAK Inhibitors and TNF Inhibitors JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for

New—Glucocorticoid-induced osteoporosis: novel concepts and clinical implications thelancet.com/journals/landi… #OpenAccess

Major Depressive Disorder and Gut Microbiota: Role of Physical Exercise pmc.ncbi.nlm.nih.gov/articles/PMC10…

🧩 SACQ Lupus (Serologically Active, Clinically Quiescent) 🔬 Definition 🧪 ↑anti-dsDNA, ↓C3/C4 ⏳ No clinical activity ≥2 yrs 📊 Prevalence 👥 ~6–15% of SLE pts 📈 Natural history 🌿 Many remain quiescent for yrs ⚡ Some flare (risk: young, ↑dsDNA, male, persistently

🌆Are you ready for the Windy City? Deep dish pizza, the Magnificent Mile and a full agenda of dynamic speakers await you at the 2025 Annual G-CAN Research Symposium in Chicago, Oct. 22-23. 👉Registration closes October 16: g-can.swoogo.com/2025. #GCAN2025.

The scariest thing in academia 😅

In 2024, 77 pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff, fever & Hi CRP/ESR - none had hip pain. 4/5 were male, w/ mean age of 55 yrs. None were RF/CCP+

Vitamin D for all SLE pts And anyone

🔬 Vaccinate First, Treat Next: The VACIMRA Lesson in Early Rheumatoid Arthritis 🧪 Study Design •Type: Multicentre, open-label, randomised trial (France) •Population: Early active RA (DAS28 >3.2), MTX/DMARD-naïve, no prior pneumococcal vaccine •Intervention: •Immediate

Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab.

Full read review of the Mechanistic Effects of Methotrexate in the Treatment of Rheumatoid Arthritis. buff.ly/vzqmEQt download here: buff.ly/143aSVi

Great!

Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over

A key component of lupus management! But HCQ blood test is out of Pocket for patients in France

📝 #Allopurinol-Related Severe Cutaneous Adverse Reactions: A Narrative Review! 👥 Authors: Edoardo Cipolletta, Satveer Mahil, Catherine H. Smith, and Abhishek Abhishek 🔗 Read the full article here: mdpi.com/2813-4583/4/1/5

Metanalysis of 8 articles, 2655 gout pts shows that ELEVATED neutrophil-to-lymphocyte ratio (NLR; SMD: 0.75; 95% CI: 0.48–1.03) and platelet-lymphocyte ratio (PLR; SMD: 0.52; 95% CI: 0.24–0.79) showed significant value in predicting acute gout attacks journals.sagepub.com/doi/10.1177/17…

🎓2025 Joint Ectopic Calcification Meeting (JECM)—Abstract Proceedings is online! 📍The 1st Joint Ectopic Calcification Meeting was held in Nancy, France, on 24–26 September 2025. 📘Full report: mdpi.com/2813-4583/4/1/6

📌Newly published paper! 📝 Non-Hyperuricemia Experimental Models of #Gout! 👥 Authors: Yevetta Xiang, An-Tzu Chien, and Christopher Hall 🔗 Full article: mdpi.com/2813-4583/4/1/8

🩻 #GCA & large vessel vasculitis — imaging matters Study shows: ➡️ 76% achieved PET/CT metabolic remission on tocilizumab ➡️ ⚠️ Persistent uptake → ↑ risk of aortic dilation ➡️ Complete extinction → very low risk 📌 PET/CT may guide prognosis & monitoring in LVV 🔗

📢 We are pleased to share that the GUCDD will be exhibiting at the 28th Asia-Pacific League of Associations for #Rheumatology Congress, which will be held from 28 October to 1 November 2026 in Seoul, Republic of Korea. 👉 Meet us at booth 17! 🔗More at: mdpi.com/about/announce…